Trial Profile
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Berotralstat (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms APeX-2
- Sponsors BioCryst Pharmaceuticals
- 19 Dec 2023 According to a BioCryst Pharmaceuticals media release, the company look forward to share additional real-world evidence at upcoming medical congresses.
- 19 Dec 2023 According to a BioCryst Pharmaceuticals media release, data from this study were published in the Journal of Allergy and Clinical Immunology.
- 19 Dec 2023 Results published in a BioCryst Pharmaceuticals Media Release.